Contact
| Email: | |
|---|---|
| Phone: | +420 54949 6695, +420 532 235 494 |
| Research group: | Functional Genomics - Michal Šmída |
| Workplace: |
24. Apr. 2020
Researchers From CEITEC Described Biomarkers That Predict Response to CAR-T Cell Cancer Therapy
Veronika Mancikova and other members of the Michal Smida Research Group from CEITEC Masaryk University, in collaboration with their colleagues from…
15. Nov. 2019
90 Dutch Students Visited CEITEC as Part of an International Science-Focused Study Trip
CEITEC Masaryk University hosted approximately 90 students from the Netherlands on 12 November 2019. The visiting students are enrolled in second and…
Publications that are part of the Web of Science database, possibly also other publications chosen by authors.
2018
- Kozlova, V; Ledererova, A; Doubek, M; Mayer, J; Pospisilova, S; Smida, M, 2018: Epigenetic Drug Screen on Resistant CLL Cells Reveals Aurora Kinase Inhibitors As Enhancers of CD20 Expression and Sensitizers to Treatment with CD20 Monoclonal Antibodies. BLOOD 132, doi: 10.1182/blood-2018-99-118669
2017
- de la Cruz, FF; Smida, M; Nijman, S, 2017: MEK inhibitors block growth of Ataxia Telangiectasia Mutated (ATM) mutant lung tumors. MOLECULAR CANCER THERAPEUTICS 16(10), doi: 10.1158/1538-8514.SYNTHLETH-PR14
- Ledererova, A; Kozlova, V; Vakulova, V; Doubek, M; Mayer, J; Pospisilova, S; Smida, M, 2017: B CELLS RESISTANT TO CD20 MONOCLONAL ANTIBODIES DISPLAY SPECIFIC ALTERATIONS IN GENE EXPRESSION PROFILE. HAEMATOLOGICA 102, p. 709 - 709
2016
- Smida, M; de la Cruz, FF; Kerzendorfer, C; Uras, IZ; Mair, B; Mazouzi, A; Suchankova, T; Konopka, T; Katz, AM; Paz, K; Nagy-Bojarszky, K; Muellner, MK; Bago-Horvath, Z; Haura, EB; Loizou, JI; Nijman, SMB, 2016: MEK inhibitors block growth of lung tumours with mutations in ataxia-telangiectasia mutated. NATURE COMMUNICATIONS 7, doi: 10.1038/ncomms13701
- Smida, M; Kozlova, V; Vakulova, V; Ledererova, A; Doubek, M; Mayer, J; Pospisilova, S, 2016: Cellular Mechanisms Regulating CD20 As a Target of Monoclonal Antibody Therapy in B-Lymphoid Malignancies. BLOOD 128(22)
2015
- Doubek, M; Smida, M, 2015: Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?. EXPERT REVIEW OF HEMATOLOGY 8(6), p. 743 - 764, doi: 10.1586/17474086.2015.1079123
- Šmída, M, 2015: Chimérický antigenní receptor T lymfocytů- genová terapie budoucnosti u nádorových onemocnění?. KLINICKÁ ONKOLOGIE
- Národní centrum lékařské genomiky (LM2015091), Ministerstvo školství, mládeže a tělovýchovy ČR, 2016 - 2019
- Rezistence na léčbu monoklonálními protilátkami u B-CLL a B-lymfomů: příčiny vzniku a potenciální intervenční strategie (15-33561A), Ministry of Health of the CR, 2015 - 2018
- CEITEC - Central European Institute of Technology (CZ.1.05/1.1.00/02.0068), Ministerstvo školství, mládeže a tělovýchovy ČR, 2011 - 2015